Long-term use of medications like metformin and proton pump inhibitors can impair vitamin B12 absorption, leading to deficiency symptoms such as fatigue, numbness, and cognitive changes. Regular B12 testing is recommended for those on these drugs to detect and treat deficiencies early.
A study suggests that long-term use (over 4.5 years) of proton pump inhibitors (PPIs), common medications for acid reflux, may be associated with a 33% increased risk of developing dementia, though it does not establish causation. The research analyzed data from over 5,700 participants and highlights the need for further investigation and consultation with healthcare providers before making changes to medication routines.
Millions of people in the UK may be at risk of medication-induced depression from common drugs like proton pump inhibitors (PPIs), antibiotics, anti-seizure drugs, and steroids. PPIs, used to reduce stomach acid, can hinder vitamin B12 absorption, potentially leading to depression. Antibiotics like fluoroquinolones may alter gut bacteria, affecting mood. Anti-seizure drugs and steroids are also linked to depression due to their effects on brain activity and stress response. Experts advise consulting a GP or pharmacist if experiencing depression as a side effect, rather than stopping medication abruptly.
A retired individual with Barrett's esophagus and concerns about the effects of proton-pump inhibitors (PPIs) on dementia and neuropathy seeks advice from Dr. Keith Roach. While studies on the link between PPIs and atrial fibrillation (AFib) are inconclusive, the risk of esophageal cancer due to untreated acid reflux in Barrett's esophagus patients is a key concern. Dr. Roach recommends PPIs over H2 blockers for reducing the risk of esophageal cancer, despite known risks such as potential B12 deficiency and neuropathy. He emphasizes the importance of routine endoscopic surveillance and biopsies for early detection and treatment of any abnormal esophageal growth.
A post hoc observational study within the Aspirin in Reducing Events in the Elderly (ASPREE) clinical trial found no increased risk for dementia or cognitive changes in older adults aged 65+ who used proton pump inhibitors (PPIs) or histamine-2 receptor antagonist (H2RA). The study concluded that long-term use of PPIs in older adults is unlikely to have negative effects on cognition. However, the study had limitations, including potential for residual confounding and underestimation of PPI and H2RA use.